256 related articles for article (PubMed ID: 23798338)
1. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
Nguyen QN; Levy LB; Lee AK; Choi SS; Frank SJ; Pugh TJ; McGuire S; Hoffman K; Kuban DA
Cancer; 2013 Sep; 119(18):3265-71. PubMed ID: 23798338
[TBL] [Abstract][Full Text] [Related]
2. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
3. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
4. High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful?
Cellini N; Pompei L; Fortuna G; Ammaturo MV; De Paula U; Luzi S; Mattiucci GC; Morganti AG; Digesù C; Rosetto ME; Palloni T; Petrongari MG; Gentile P; Deodato F; Valentini V
Tumori; 2004; 90(2):201-7. PubMed ID: 15237583
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.
Zelefsky MJ; Pei X; Chou JF; Schechter M; Kollmeier M; Cox B; Yamada Y; Fidaleo A; Sperling D; Happersett L; Zhang Z
Eur Urol; 2011 Dec; 60(6):1133-9. PubMed ID: 21889832
[TBL] [Abstract][Full Text] [Related]
6. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
7. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
[TBL] [Abstract][Full Text] [Related]
8. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
Liauw SL; Stadler WM; Correa D; Weichselbaum RR; Jani AB
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):125-30. PubMed ID: 19695789
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
[TBL] [Abstract][Full Text] [Related]
10. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
11. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
[TBL] [Abstract][Full Text] [Related]
12. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
13. The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms.
Stoyanova R; Pahlajani NH; Egleston BL; Buyyounouski MK; Chen DY; Horwitz EM; Pollack A
Cancer; 2013 Mar; 119(5):1080-8. PubMed ID: 23096533
[TBL] [Abstract][Full Text] [Related]
14. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
[TBL] [Abstract][Full Text] [Related]
15. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
[TBL] [Abstract][Full Text] [Related]
16. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
Hussain M; Tangen CM; Thompson IM; Swanson GP; Wood DP; Sakr W; Dawson NA; Haas NB; Flaig TW; Dorff TB; Lin DW; Crawford ED; Quinn DI; Vogelzang NJ; Glode LM
J Clin Oncol; 2018 May; 36(15):1498-1504. PubMed ID: 29624463
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
18. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less.
Parekh A; Chen MH; Graham P; Mahal BA; Hirsch AE; Nakabayashi M; Evan C; Kantoff PW; Martin NE; Nguyen PL
Clin Genitourin Cancer; 2015 Feb; 13(1):e1-6. PubMed ID: 25103271
[TBL] [Abstract][Full Text] [Related]
19. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
Zagars GK; Pollack A; Smith LG
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
[TBL] [Abstract][Full Text] [Related]
20. Impact of radiation dose on recurrence in high-risk prostate cancer patients.
Deek M; Lilleby W; Vaage V; Hole KH; DeWeese T; Stensvold A; Tran P; Seierstad T
Prostate; 2020 Nov; 80(15):1322-1327. PubMed ID: 33258482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
